跳至主要内容
临床试验/NCT00480649
NCT00480649已完成4 期

SUccessful Control and Clinical Effectiveness of SERETIDE Study in aSthma, a Randomised Controlled Study to Investigate the Clinical Effectiveness and Health Outcome of SERETIDE in Patients With Moderate and Severe Persistent Asthma in Korea

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 424 人开始时间: 2004年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
424
试验地点
1
主要终点
The primary efficacy endpoint for this trial is mean morning PEFR LOCF at 52 weeks as collected in diary cards over the last 2 weeks preceding the 52 weeks visit.

研究概览

简要总结

The primary study objective is to demonstrate the clinical effectiveness of SERETIDE therapy compared to the current care in management of moderate to severe persistent asthma patients in Korea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Sal/FP 50/250mcg

Active Comparator

SERETIDE 50/250

干预措施: Salmeterol/ fluticasone propionate (Drug)

Sal/FP 50/500mcg

Active Comparator

SERETIDE 50/500

干预措施: Salmeterol/ fluticasone propionate (Drug)

结局指标

主要结局

The primary efficacy endpoint for this trial is mean morning PEFR LOCF at 52 weeks as collected in diary cards over the last 2 weeks preceding the 52 weeks visit.

时间窗: 52 weeks after randomization

次要结局

  • Secondary measures of efficacy consist of clinical efficacy and health outcome measurements.(52 weeks after randomization)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验